<?xml version='1.0' encoding='utf-8'?>
<document id="24911450"><sentence text="Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban."><entity charOffset="105-113" id="DDI-PubMed.24911450.s1.e0" text="edoxaban" /></sentence><sentence text="Edoxaban is an oral direct factor Xa (FXa) inhibitor and its efficacy as an oral anticoagulant is less subject to drug-food and drug-drug interaction than existing vitamin K antagonists"><entity charOffset="0-8" id="DDI-PubMed.24911450.s2.e0" text="Edoxaban" /><entity charOffset="164-173" id="DDI-PubMed.24911450.s2.e1" text="vitamin K" /><pair ddi="false" e1="DDI-PubMed.24911450.s2.e0" e2="DDI-PubMed.24911450.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24911450.s2.e0" e2="DDI-PubMed.24911450.s2.e1" /></sentence><sentence text=" Although this profile of edoxaban suggests it is well suited for clinical use, it is not clear whether genetic variations of factor X influence the activity of edoxaban"><entity charOffset="26-34" id="DDI-PubMed.24911450.s3.e0" text="edoxaban" /><entity charOffset="161-169" id="DDI-PubMed.24911450.s3.e1" text="edoxaban" /><pair ddi="false" e1="DDI-PubMed.24911450.s3.e0" e2="DDI-PubMed.24911450.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24911450.s3.e0" e2="DDI-PubMed.24911450.s3.e1" /></sentence><sentence text=" Our aim was to investigate a possible impact of single-nucleotide polymorphisms (SNPs) in the factor X gene on the functions of factor X and the activity of edoxaban"><entity charOffset="158-166" id="DDI-PubMed.24911450.s4.e0" text="edoxaban" /></sentence><sentence text=" Two nonsynonymous SNPs within mature factor X, Ala152Thr and Gly192Arg, were selected as possible candidates that might affect the functions of FXa and the activity of edoxaban"><entity charOffset="169-177" id="DDI-PubMed.24911450.s5.e0" text="edoxaban" /></sentence><sentence text=" We measured catalytic activities of wild type and mutant FXas in a chromogenic assay using S-2222 and coagulation times including prothrombin time (PT) and activated partial thrombin time (aPTT) of plasma-containing recombinant FXs in the presence and absence of edoxaban"><entity charOffset="264-272" id="DDI-PubMed.24911450.s6.e0" text="edoxaban" /></sentence><sentence text=" Michaelis-Menten kinetic parameters of FXas, Km and Vmax values, PT and aPTT were not influenced by either mutation indicating these mutations do not affect the FXa catalytic and coagulation activities" /><sentence text=" The Ki values of edoxaban for the FXas and the concentrations of edoxaban required to double PT and aPTT were not different between wild type and mutated FXas indicating that both mutations have little impact on the activity of edoxaban"><entity charOffset="18-26" id="DDI-PubMed.24911450.s8.e0" text="edoxaban" /><entity charOffset="66-74" id="DDI-PubMed.24911450.s8.e1" text="edoxaban" /><entity charOffset="229-237" id="DDI-PubMed.24911450.s8.e2" text="edoxaban" /><pair ddi="false" e1="DDI-PubMed.24911450.s8.e0" e2="DDI-PubMed.24911450.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24911450.s8.e0" e2="DDI-PubMed.24911450.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24911450.s8.e0" e2="DDI-PubMed.24911450.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24911450.s8.e1" e2="DDI-PubMed.24911450.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24911450.s8.e1" e2="DDI-PubMed.24911450.s8.e2" /></sentence><sentence text=" In conclusion, these data suggest that edoxaban has little interpatient variability stemming from SNPs in the factor X gene"><entity charOffset="40-48" id="DDI-PubMed.24911450.s9.e0" text="edoxaban" /></sentence><sentence text=" " /></document>